TP53 and hepatocellular carcinoma: Finally, Carol Prives (New York, USA) received the 2019 CDD Award presenting her work on the p53 control of the mevalonate pathway via the sterol regulatory element-binding protein 2, which represents an early event for hepatocellular carcinoma (HCC) development.